RU2368620C2 - ПРОИЗВОДНЫЕ PhI p 5а, ОБЛАДАЮЩИЕ СНИЖЕННОЙ АЛЛЕРГЕННОСТЬЮ И СОХРАНЕННОЙ Т-КЛЕТОЧНОЙ РЕАКТИВНОСТЬЮ - Google Patents
ПРОИЗВОДНЫЕ PhI p 5а, ОБЛАДАЮЩИЕ СНИЖЕННОЙ АЛЛЕРГЕННОСТЬЮ И СОХРАНЕННОЙ Т-КЛЕТОЧНОЙ РЕАКТИВНОСТЬЮ Download PDFInfo
- Publication number
- RU2368620C2 RU2368620C2 RU2005141524/13A RU2005141524A RU2368620C2 RU 2368620 C2 RU2368620 C2 RU 2368620C2 RU 2005141524/13 A RU2005141524/13 A RU 2005141524/13A RU 2005141524 A RU2005141524 A RU 2005141524A RU 2368620 C2 RU2368620 C2 RU 2368620C2
- Authority
- RU
- Russia
- Prior art keywords
- phi
- allergens
- allergen
- variant
- reactivity
- Prior art date
Links
- 230000009257 reactivity Effects 0.000 title claims abstract description 28
- 230000000717 retained effect Effects 0.000 title abstract description 4
- 230000003247 decreasing effect Effects 0.000 title abstract 3
- 230000002009 allergenic effect Effects 0.000 title description 7
- 239000013566 allergen Substances 0.000 claims abstract description 94
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 44
- 230000007815 allergy Effects 0.000 claims abstract description 40
- 108020004414 DNA Proteins 0.000 claims abstract description 19
- 241001330029 Pooideae Species 0.000 claims abstract description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 16
- 239000013604 expression vector Substances 0.000 claims abstract description 12
- 102000053602 DNA Human genes 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 5
- 238000003259 recombinant expression Methods 0.000 claims abstract description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 3
- 230000002829 reductive effect Effects 0.000 claims description 17
- 238000010353 genetic engineering Methods 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 229960004784 allergens Drugs 0.000 abstract description 43
- 239000000126 substance Substances 0.000 abstract description 15
- 229940046528 grass pollen Drugs 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 10
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract description 5
- 238000002360 preparation method Methods 0.000 abstract description 5
- 206010048908 Seasonal allergy Diseases 0.000 abstract description 3
- 201000004338 pollen allergy Diseases 0.000 abstract description 3
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 238000012407 engineering method Methods 0.000 abstract 1
- 238000012217 deletion Methods 0.000 description 53
- 230000037430 deletion Effects 0.000 description 53
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 27
- 150000001413 amino acids Chemical group 0.000 description 26
- 208000026935 allergic disease Diseases 0.000 description 22
- 239000002299 complementary DNA Substances 0.000 description 22
- 230000027455 binding Effects 0.000 description 20
- 239000012634 fragment Substances 0.000 description 17
- 210000002966 serum Anatomy 0.000 description 16
- 230000000172 allergic effect Effects 0.000 description 13
- 208000010668 atopic eczema Diseases 0.000 description 13
- 238000004458 analytical method Methods 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 12
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 10
- 238000003752 polymerase chain reaction Methods 0.000 description 10
- 210000003651 basophil Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000010998 test method Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000003556 assay Methods 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 102000037865 fusion proteins Human genes 0.000 description 6
- 108020001507 fusion proteins Proteins 0.000 description 6
- 241000746983 Phleum pratense Species 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000209048 Poa Species 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 230000001024 immunotherapeutic effect Effects 0.000 description 4
- 238000001155 isoelectric focusing Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 238000004132 cross linking Methods 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 102100021935 C-C motif chemokine 26 Human genes 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000897493 Homo sapiens C-C motif chemokine 26 Proteins 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 240000004296 Lolium perenne Species 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001605702 Mylothris Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000209049 Poa pratensis Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 229940074608 allergen extract Drugs 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010188 recombinant method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 241000238876 Acari Species 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- -1 Lollum perenne Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000516 activation analysis Methods 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000013574 grass pollen allergen Substances 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10325508 | 2003-06-04 | ||
| DE10325508.7 | 2003-06-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005141524A RU2005141524A (ru) | 2006-09-10 |
| RU2368620C2 true RU2368620C2 (ru) | 2009-09-27 |
Family
ID=33494849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005141524/13A RU2368620C2 (ru) | 2003-06-04 | 2004-05-06 | ПРОИЗВОДНЫЕ PhI p 5а, ОБЛАДАЮЩИЕ СНИЖЕННОЙ АЛЛЕРГЕННОСТЬЮ И СОХРАНЕННОЙ Т-КЛЕТОЧНОЙ РЕАКТИВНОСТЬЮ |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8628946B2 (enExample) |
| EP (3) | EP2272863B1 (enExample) |
| JP (2) | JP4782671B2 (enExample) |
| CN (1) | CN1798763B (enExample) |
| AT (1) | ATE513848T1 (enExample) |
| AU (1) | AU2004245184B2 (enExample) |
| BR (1) | BRPI0410908A (enExample) |
| CA (1) | CA2528053C (enExample) |
| ES (3) | ES2397778T3 (enExample) |
| PL (2) | PL2287180T3 (enExample) |
| PT (3) | PT2272863E (enExample) |
| RU (1) | RU2368620C2 (enExample) |
| WO (1) | WO2004108758A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPR779201A0 (en) | 2001-09-20 | 2001-10-11 | University Of Melbourne, The | Immunotherapeutic and immunoprophylactic reagents |
| US8628946B2 (en) * | 2003-06-04 | 2014-01-14 | Merck Patent Gmbh | Phl p 5a derivatives having reduced allergeneity and retained T-cell reactivity |
| AT503690A1 (de) * | 2006-06-09 | 2007-12-15 | Biomay Ag | Hypoallergene moleküle |
| EP3170510A1 (de) * | 2010-01-14 | 2017-05-24 | Merck Patent GmbH | Varianten der gruppe 5-allergene der süssgräser mit reduzierter allergenität durch mutagenese von prolinresten |
| US20230242922A1 (en) | 2021-09-13 | 2023-08-03 | Life Technologies Corporation | Gene editing tools |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5736362A (en) * | 1990-10-26 | 1998-04-07 | The University Of Melbourne | Ryegrass pollen allergen |
| DE19713001A1 (de) | 1997-03-27 | 1998-10-01 | Merck Patent Gmbh | Graminaenpollenallergenmutanten zur spezifischen Immuntherapie, deren Herstellung und Verwendung |
| DE19918682A1 (de) | 1999-04-23 | 2000-10-26 | Merck Patent Gmbh | DNA-Sequenz und rekombinante Herstellung eines Graminaen-Allergens |
| IT1318692B1 (it) | 2000-09-12 | 2003-08-27 | Consiglio Nazionale Ricerche | Varianti di proteine allergeniche di phleum pratense. |
| DE60136653D1 (de) * | 2000-11-16 | 2009-01-02 | Alk Abello As | Mutante allergene |
| AUPR779201A0 (en) * | 2001-09-20 | 2001-10-11 | University Of Melbourne, The | Immunotherapeutic and immunoprophylactic reagents |
| US8628946B2 (en) * | 2003-06-04 | 2014-01-14 | Merck Patent Gmbh | Phl p 5a derivatives having reduced allergeneity and retained T-cell reactivity |
-
2004
- 2004-05-06 US US10/559,272 patent/US8628946B2/en not_active Expired - Fee Related
- 2004-05-06 ES ES10009855T patent/ES2397778T3/es not_active Expired - Lifetime
- 2004-05-06 EP EP10009855A patent/EP2272863B1/de not_active Expired - Lifetime
- 2004-05-06 RU RU2005141524/13A patent/RU2368620C2/ru not_active IP Right Cessation
- 2004-05-06 ES ES04739147T patent/ES2367633T3/es not_active Expired - Lifetime
- 2004-05-06 ES ES10009856T patent/ES2434720T3/es not_active Expired - Lifetime
- 2004-05-06 CN CN200480015311XA patent/CN1798763B/zh not_active Expired - Fee Related
- 2004-05-06 JP JP2006508164A patent/JP4782671B2/ja not_active Expired - Fee Related
- 2004-05-06 PL PL10009856T patent/PL2287180T3/pl unknown
- 2004-05-06 EP EP04739147A patent/EP1629006B1/de not_active Expired - Lifetime
- 2004-05-06 EP EP10009856.5A patent/EP2287180B9/de not_active Expired - Lifetime
- 2004-05-06 PL PL10009855T patent/PL2272863T3/pl unknown
- 2004-05-06 WO PCT/EP2004/004848 patent/WO2004108758A1/de not_active Ceased
- 2004-05-06 AT AT04739147T patent/ATE513848T1/de active
- 2004-05-06 PT PT100098557T patent/PT2272863E/pt unknown
- 2004-05-06 BR BRPI0410908-2A patent/BRPI0410908A/pt not_active IP Right Cessation
- 2004-05-06 CA CA2528053A patent/CA2528053C/en not_active Expired - Fee Related
- 2004-05-06 PT PT04739147T patent/PT1629006E/pt unknown
- 2004-05-06 PT PT100098565T patent/PT2287180E/pt unknown
- 2004-05-06 AU AU2004245184A patent/AU2004245184B2/en not_active Ceased
-
2010
- 2010-09-16 JP JP2010207438A patent/JP5363441B2/ja not_active Expired - Fee Related
-
2014
- 2014-01-02 US US14/146,364 patent/US9522938B2/en not_active Expired - Fee Related
-
2016
- 2016-04-05 US US15/090,935 patent/US20160207967A1/en not_active Abandoned
Non-Patent Citations (1)
| Title |
|---|
| ФРАДКИН В.А. Аллергены, Изд. Медицина, М., 1978, с.125-139. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9556241B2 (en) | DNA sequence and preparation of grass pollen allergen Phl p 4 by recombinant methods | |
| JP5363441B2 (ja) | 低減したアレルギー誘発性および保持されたＴ細胞反応性を有するＰｈｌｐ５ａ誘導体 | |
| US7241450B1 (en) | DNA sequence and recombinant production of a Gramineae allergen | |
| RU2409589C2 (ru) | ВАРИАНТ АЛЛЕРГЕНА ГРУППЫ I ИЗ Роасеае, ХАРАКТЕРИЗУЮЩИЙСЯ СНИЖЕННОЙ АЛЛЕРГЕННОСТЬЮ И СОХРАНЕННОЙ Т-КЛЕТОЧНОЙ РЕАКТИВНОСТЬЮ (ВАРИАНТЫ), КОДИРУЮЩАЯ ЕГО МОЛЕКУЛА ДНК И ЕГО ПРИМЕНЕНИЕ | |
| RU2373283C2 (ru) | Последовательность днк и рекомбинантное получение основных аллергенов группы 4 из злаковых | |
| JP2007536893A5 (enExample) | ||
| RU2607373C2 (ru) | Модификации аллергенов группы 6 poaceae (мятликовых), имеющих пониженную аллергенность благодаря мутагенезу пролиновых остатков | |
| JP2013516962A (ja) | プロリン残基の突然変異誘発により低減したアレルゲン性を有するイネ科のグループ５アレルゲンの変異体 | |
| AU2011202726B2 (en) | DNA-sequence and recombinant production of group 4 major allergens from cereals |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20180507 |